Literature DB >> 12674499

Different sensitivities of mutants and chimeric forms of human muscle and liver fructose-1,6-bisphosphatases towards AMP.

Dariusz Rakus1, Harald Tillmann, Robert Wysocki, Stanislaw Ulaszewski, Klaus Eschrich, Andrzej Dzugaj.   

Abstract

AMP is an allosteric inhibitor of human muscle and liver fructose-1,6-bisphosphatase (FBPase). Despite strong similarity of the nucleotide binding domains, the muscle enzyme is inhibited by AMP approximately 35 times stronger than liver FBPase: I0.5 for muscle and for liver FBPase are 0.14 microM and 4.8 microM, respectively. Chimeric human muscle (L50M288) and chimeric human liver enzymes (M50L288), in which the N-terminal residues (1-50) were derived from the human liver and human muscle FBPases, respectively, were inhibited by AMP 2-3 times stronger than the wild-type liver enzyme. An amino acid exchange within the N-terminal region of the muscle enzyme towards liver FBPase (Lys20-->Glu) resulted in 13-fold increased I0.5 values compared to the wild-type muscle enzyme. However, the opposite exchanges in the liver enzyme (Glu20-->Lys and double mutation Glu19-->Asp/Glu20-->Lys) did not change the sensitivity for AMP inhibition of the liver mutant (I0.5 value of 4.9 microM). The decrease of sensitivity for AMP of the muscle mutant Lys20-->Glu, as well as the lack of changes in the inhibition by AMP of liver mutants Glu20-->Lys and Glu19-->Asp/Glu20-->Lys, suggest a different mechanism of AMP binding to the muscle and liver enzyme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12674499     DOI: 10.1515/BC.2003.006

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

1.  Cobalt Regulates Activation of Camk2α in Neurons by Influencing Fructose 1,6-bisphosphatase 2 Quaternary Structure and Subcellular Localization.

Authors:  Przemysław Duda; Bartosz Budziak; Dariusz Rakus
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

2.  T-to-R switch of muscle fructose-1,6-bisphosphatase involves fundamental changes of secondary and quaternary structure.

Authors:  Jakub Barciszewski; Janusz Wisniewski; Robert Kolodziejczyk; Mariusz Jaskolski; Dariusz Rakus; Andrzej Dzugaj
Journal:  Acta Crystallogr D Struct Biol       Date:  2016-03-30       Impact factor: 7.652

Review 3.  Targeting FBPase is an emerging novel approach for cancer therapy.

Authors:  Gao-Min Liu; Yao-Ming Zhang
Journal:  Cancer Cell Int       Date:  2018-03-09       Impact factor: 5.722

4.  Fructose 1,6-Bisphosphatase 2 Plays a Crucial Role in the Induction and Maintenance of Long-Term Potentiation.

Authors:  Przemysław Duda; Tomasz Wójtowicz; Jakub Janczara; Daniel Krowarsch; Aleksandra Czyrek; Agnieszka Gizak; Dariusz Rakus
Journal:  Cells       Date:  2020-06-01       Impact factor: 6.600

5.  The mechanism of calcium-induced inhibition of muscle fructose 1,6-bisphosphatase and destabilization of glyconeogenic complex.

Authors:  Dariusz Rakus; Agnieszka Gizak; Andrzej A Kasprzak; Marek Zarzycki; Ewa Maciaszczyk-Dziubinska; Andrzej Dzugaj
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

6.  Crystal structures of human muscle fructose-1,6-bisphosphatase: novel quaternary states, enhanced AMP affinity, and allosteric signal transmission pathway.

Authors:  Rong Shi; Ze-Yong Chen; Dao-Wei Zhu; Chunmin Li; Yufei Shan; Genjun Xu; Sheng-Xiang Lin
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

7.  Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell.

Authors:  Janusz Wiśniewski; Michał Piróg; Rafał Hołubowicz; Piotr Dobryszycki; James A McCubrey; Dariusz Rakus; Agnieszka Gizak
Journal:  Oncotarget       Date:  2017-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.